
PRESS RELEASE

STOCKHOLM, 10 DECEMBER 2018

RaySearch expands product line-up with a treatment control system, RayCommand, and receives order from AVO

RaySearch has decided to develop a treatment control system, RayCommand. The first customer will be Advanced Oncotherapy plc (AVO), a UK based developer of next generation proton therapy technology. AVO will use it for the first LIGHT (Linac Image Guided Hadron Technology) system at the proton therapy facility under construction at Harley Street in central London, UK.

RaySearch's main product today is RayStation, a treatment planning system for radiation therapy. It is used to produce a sequence of settings for the treatment machine, a so-called treatment plan, designed to produce an optimal distribution of dose in a patient, targeting regions with cancer cells and avoiding surrounding tissues. The planning process involves detailed modeling of patient anatomy and treatment machine components in order to accurately predict and optimize the delivered dose distribution.

By the end of 2017, RaySearch released the first version of its oncology information system (OIS), RayCare*. An OIS is used to coordinate all the complex procedures that are involved in a comprehensive cancer treatment regime. This includes handling of diagnostic studies and consultation notes, facilitating tumor board meetings, scheduling of resources, data collection, charge capture and follow-up of treatment outcome. RayCare is designed around patient centric digital workflows that help increase efficiency and quality of care.

Now, RaySearch has decided to develop a treatment control system (TCS), RayCommand. A TCS is the link between the TPS and OIS on one side and the treatment machine on the other. It coordinates and orchestrates the different systems involved, such as the imaging systems, the beam delivery system and the patient support system. This is critical in order to achieve safe and efficient patient treatments. For multi-room proton therapy installation, there is also the extra dimension of coordinating activities between treatment rooms to maximize beam utilization and minimize wait times.

The decision to build a TCS is connected to an order from AVO for its first proton therapy facility. AVO has previously purchased RayStation and RayCare for the facility and has now also ordered RayCommand. This means that this AVO facility will be the first clinic to use an all RaySearch software suite with both TPS, OIS and TCS. Tight integration between these systems will ensure a safe and efficient treatment process. RayCommand will build on the user friendliness and attention to detail in RayStation and RayCare.

Another important aspect of RayCommand will be to enable online adaptive radiation therapy. Support for offline treatment adaptation has been a key feature in RayStation for many years, but clinical implementation together with the other OIS:es on the market was cumbersome, which RayCare overcomes. But for online treatment adaptations, the TCS must also be involved and many

existing TCS are not designed for this. RaySearch is confident that RayCare, RayStation and RayCommand will provide an overall user experience of the highest standards.

Nicolas Serandour, CEO AVO, says: "RayStation was the obvious choice for TPS to complement our advanced particle therapy treatment technology. It is also clear to us that RayCare represents the next generation in the OIS field. Likewise, for TCS, we wished to offer a next generation system to take full advantage of the LIGHT capabilities. We are pleased that RaySearch decided to move into this field and work together with us to create a fully integrated solution with our technology. The unified TPS-OIS-TCS-LIGHT chain is expected to bring the prospect of truly personalized medicine to our proton therapy installations."

Johan Löf, CEO RaySearch, says: "We are all on the same side in the fight against cancer and it is by working together in an environment with both competitors and partners that we can achieve the most. By introducing RayCommand, an open and independent TCS, we can enable more vendors to provide best in class solutions for the treatment room. AVO is an excellent example of such a vendor and we are excited to work together with them to advance cancer treatment."

The order value for RayCommand is 3,6 MEUR and is anticipated to generate revenues of circa 1,8 MEUR within the next 12 months and the remaining part within 36 months.

This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 13.42 CET on 10/12 2018.

About Advanced Oncotherapy

Advanced Oncotherapy plc (AVO) is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team Applications of Detectors and Accelerators to Medicine (ADAM SA), based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control. Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment-related side effects. Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. For more information go to: www.avopl.com

About RaySearch

RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare, the next-generation oncology information system, worldwide. Over 2,600 clinics in more than 65 countries use RaySearch's software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

About RayCare

RayCare is designed to support the complex logistical challenges of modern oncology clinics. It represents the future of oncology information system technology, supporting the vision of one oncology workflow. Many cancer patients receive a combination of treatment types, and RayCare is designed to reflect that. It will efficiently coordinate activities in radiation therapy, chemotherapy and surgery and will offer advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. RayCare is being developed with tomorrow's requirements for advanced analytics and decision support in mind.

About RayStation

RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.

More information about RaySearch is available at www.raysearchlabs.com

* Subject to regulatory clearance in some markets.

For further information, please contact:

Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

Telephone: +46 (0)8-510 530 00

johan.lof@raysearchlabs.com

Peter Thysell, CFO, RaySearch Laboratories AB (publ)

Telephone: +46 (0)70 661 05 59

peter.thysell@raysearchlabs.com